BRAIN Biotech AG reported earnings results for the second quarter and six months ended March 31, 2024. For the second quarter, the company reported sales was EUR 14.47 million compared to EUR 13.48 million a year ago. Revenue was EUR 14.28 million compared to EUR 14.6 million a year ago. Net loss was EUR 1.92 million compared to EUR 2.27 million a year ago. Basic loss per share from continuing operations was EUR 0.09 compared to EUR 0.1 a year ago. Diluted loss per share from continuing operations was EUR 0.09 compared to EUR 0.1 a year ago.
For the six months, sales was EUR 27.2 million compared to EUR 27.17 million a year ago. Revenue was EUR 27.36 million compared to EUR 28.09 million a year ago. Net loss was EUR 4.56 million compared to EUR 4.8 million a year ago. Basic loss per share from continuing operations was EUR 0.21 compared to EUR 0.22 a year ago. Diluted loss per share from continuing operations was EUR 0.21 compared to EUR 0.22 a year ago.